Somewhat Favorable News Coverage Somewhat Unlikely to Impact Organovo (NASDAQ:ONVO) Stock Price

Media coverage about Organovo (NASDAQ:ONVO) has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Organovo earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 47.9288765116156 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Organovo (ONVO) opened at $1.41 on Monday. Organovo has a 1 year low of $1.32 and a 1 year high of $3.85. The firm has a market capitalization of $150.76, a price-to-earnings ratio of -3.71 and a beta of 2.61.

Organovo (NASDAQ:ONVO) last posted its earnings results on Thursday, November 9th. The medical research company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $1.36 million during the quarter, compared to the consensus estimate of $1.38 million. Organovo had a negative return on equity of 65.63% and a negative net margin of 923.89%. Organovo’s quarterly revenue was down 1.4% compared to the same quarter last year. equities analysts forecast that Organovo will post -0.36 EPS for the current year.

Several analysts recently weighed in on the company. Zacks Investment Research downgraded Organovo from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th. BTIG Research restated a “buy” rating and set a $3.00 price objective on shares of Organovo in a research report on Thursday, November 16th. Citigroup downgraded Organovo to a “market perform” rating in a research report on Friday, November 10th. Finally, Raymond James Financial downgraded Organovo from an “outperform” rating to a “market perform” rating and set a $5.00 price objective for the company. in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $3.60.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Organovo (NASDAQ:ONVO) Stock Price” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at

Organovo Company Profile

Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Insider Buying and Selling by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with's FREE daily email newsletter.

Leave a Reply